[PRNewswire] Insilico Medicine Announces First-in-Human Study
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"IBD impacts a large patient population who currently have limited therapeutic options," says Sujata Rao, MD, Chief Medical Officer at Insilico Medicine who is leading the clinical trial. "We believe this new treatment - which is potentially first-in-class - could offer a promising alternative."
"The rising incidence of IBD places a heavy burden on healthcare systems globally," said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. "Designed by AI from scratch, ISM5411 targets mucosal healing with the unique mechanism of barrier protection enhancement, which could potentially lead to innovative clinical options for IBD patients. We are committed to accelerating ISM5411 clinical trials to reach unmet clinical needs as soon as possible."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
-- The study is for orally PHD inhibitor ISM5411 for inflammatory bowel disease (IBD)
- ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes.
- ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the first dose of healthy subjects completed in Australia.
- To further evaluate ISM5411 in wider populations, Insilico plans to conduct global, multi-center Phase Ib trials in patients with ulcerative colitis following the Phase Ia study.
NEW YORK and HONG KONG Dec 5, 2023 /PRNewswire=연합뉴스/ -- Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially first-in-class PHD inhibitor for the treatment of inflammatory bowel disease (IBD).
Developed by Insilico's proprietary end-to-end AI drug discovery platform, Pharma.AI, ISM5411 is Insilico's fifth AI drug program to enter the clinic. The ongoing Phase I study[https://classic.clinicaltrials.gov/ct2/show/NCT06012578?term=ISM5411-101&draw=2&rank=1 ] is designed to evaluate the safety, tolerability, pharmacokinetics and food effects of ISM5411 at increasing oral doses in 76 healthy subjects, with the first dose in healthy volunteers now completed in Australia. To further evaluate ISM5411 in wider populations, Insilico plans to conduct global multi-center Phase Ib trials in patients with ulcerative colitis following the Phase Ia study.
"IBD impacts a large patient population who currently have limited therapeutic options," says Sujata Rao, MD, Chief Medical Officer at Insilico Medicine who is leading the clinical trial. "We believe this new treatment - which is potentially first-in-class - could offer a promising alternative."
IBD[https://pubmed.ncbi.nlm.nih.gov/24833941/ ] is a chronic inflammatory disease of the gastrointestinal tract, including ulcerative colitis (UC) and Crohn's disease (CD), that affects huge populations globally, and 2 million adults in the U.S. alone. Neither disorder is curable, and they both increase the risk of colorectal cancer up to four times. The current standard of treatment for IBD consists of anti-inflammatory drugs which offer limited improvement in mucosal healing, which is closely correlated to positive prognosis according to genetic and clinical evidence.
Research shows that PHD plays a critical role in regulating the stability and transcriptional activity of the hypoxia-inducible factor-1α (HIF-1α), which drives the expression of barrier protective genes. PHD is significantly up regulated in IBD patients, and shows strong correlation with the expression of inflammatory cytokines and the apoptosis marker, suggesting that PHD is a potential target for IBD treatment.
In January 2022, Insilico announced the nomination of ISM5411 as a preclinical drug candidate (PCC) for the treatment of IBD targeting PHD. ISM5411 was developed by Chemistry42, Insilico's generative AI engine for molecule development, and features a novel scaffold and a unique binding mode. In preclinical studies, ISM5411 demonstrated a favorable safety profile and significant anti-colitis efficacy as an oral, gut-restricted small molecule inhibitor.
"The rising incidence of IBD places a heavy burden on healthcare systems globally," said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. "Designed by AI from scratch, ISM5411 targets mucosal healing with the unique mechanism of barrier protection enhancement, which could potentially lead to innovative clinical options for IBD patients. We are committed to accelerating ISM5411 clinical trials to reach unmet clinical needs as soon as possible."
Driven by generative artificial intelligence, Insilico stands at the intersection of artificial intelligence and state-of-art technologies. The company has developed a comprehensive portfolio of more than 30 pipelines with 5 programs currently in the clinical stage developed using Pharma.AI, an integrated AI-driven drug discovery platform connecting biology, chemistry, and clinical development. Recently, Insilico launched the Company's Al R&D Center in Montreal, Canada to further strengthen its AI algorithm research and platform building capabilities.
"At Insilico, we are driven to help patients in need using state-of-the-art AI technology combined with human ingenuity," said Alex Zhavoronkov, PhD, Founder and co-CEO of Insilico Medicine. "This IBD program is the latest example of how we are using our AI algorithms to advance new cures for difficult-to-treat diseases."
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
www.insilico.com
Source: Insilico Medicine
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 전세사기 특별단속 2년간 8천여명 검거…1만6천명에 2조 피해 | 연합뉴스
- 검찰, 딸 자택 압수수색 영장에 문재인 전 대통령 피의자로 적시 | 연합뉴스
- 평균소득 벌면 오늘부터 수도권 주담대 한도 5천500만원 축소 | 연합뉴스
- "응급실만 연다고 환자 받을 수 있나" 핵심은 배후진료 위기 | 연합뉴스
- [2보] 8월 수출 11.4%↑ '11개월 연속 플러스'…무역흑자 38.3억달러 | 연합뉴스
- 20∼40세대 43% "출산 안해"…女 "필요 못느껴" 男 "여유없어" | 연합뉴스
- 대구 동구 도로서 길이 50㎝·깊이 1.7m 지반 침하 | 연합뉴스
- [기후 격변] ① '쏘이고, 찢기고'…동해안 최북단까지 습격한 해파리 | 연합뉴스
- 서울 아파트 40대가 가장 많이 샀다…23개월 만에 30대 추월 | 연합뉴스
- 올해, 열대야 가장 많았던 해…'사상최악 폭염' 2018년보다 많아 | 연합뉴스